Hearing News Watch

Hearing Health & Technology Matters (HHTM) is excited to announce the launch of the Hearing Therapeutics Summit, a premier virtual event taking place February 4–5, 2025. This highly-anticipated symposium will bring together experts, researchers, and industry leaders to share insights and explore the latest developments in hearing therapeutics. Attendees can look forward to an engaging program highlighting key advancements, emerging

In a significant policy shift, the Department of the Air Force (DAF) has updated its medical waiver guidelines for hearing loss, offering a pathway for more individuals with mild to moderate hearing impairments to serve. This change, part of a broader overhaul that also addresses asthma and food allergies, reflects evolving medical standards and advancements in hearing aid and assistive

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat, and prevent hearing loss disorders, today announced the completion of enrollment for the first cohort of its Audiogene Phase 1/2 gene therapy clinical trial. Successful Completion of First Cohort Enrollment Marks Key Milestone Recruitment of the first cohort,

For decades, Auditory Brainstem Response (ABR) testing has been a cornerstone in audiology, primarily used for assessing hearing thresholds in infants, difficult-to-test populations, and individuals with suspected auditory nerve or brainstem disorders. By measuring the brain’s electrical responses to sound stimuli, ABR offers an objective, non-invasive assessment of auditory pathway integrity. However, a recent study published in Communications Biology reveals

A new study published in PLOS ONE investigates how older adults with cochlear implants (CIs) manage attention and memory across auditory and visual tasks. The research, led by Amisha Ojha and colleagues, aims to understand whether hearing restoration through cochlear implants affects cognitive functions such as reflective attention—a process that allows individuals to focus on specific memories or details held

Medicare beneficiaries relying on telehealth services for audiology care may face significant barriers starting January 1, 2025, as the Centers for Medicare & Medicaid Services (CMS) plans to end coverage for these services. An article published this week in JAMA Otolaryngology–Head & Neck Surgery highlights the implications of this decision, which threatens to reverse progress made in improving access to

No excerpt

LONDON, UNITED KINGDOM — The National Institute for Health and Care Excellence (NICE) has recommended a new treatment aimed at preventing and reducing hearing loss in patients undergoing cisplatin chemotherapy. This marks a significant step forward in addressing a common and often debilitating side effect of a widely used cancer treatment. Cisplatin is a chemotherapy drug commonly administered to treat various

MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in therapies to restore, treat, and prevent hearing loss disorders, has announced promising data from the first two patients treated in the Audiogene Phase 1/2 clinical trial evaluating SENS-501. This trial focuses on infants and toddlers aged 6 to 31 months who suffer from a specific form of

EDEN PRAIRIE, MINNESOTA – Starkey has announced that its Founder and Chairman, William F. Austin, has been awarded an honorary degree from Kenyatta University in recognition of his groundbreaking contributions to hearing healthcare and his unwavering commitment to serving disadvantaged communities in Africa and throughout the world. Bill Austin’s vision and generosity have touched millions of lives around the globe.